You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antigens,%20BCMA

Showing 1 - 25 of 882
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in United States (SEA-BCMA, dexamethasone, pomalidomide)

Recruiting
  • Multiple Myeloma
  • Palo Alto, California
  • +10 more
Aug 24, 2022

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Multiple Myeloma Trial in Suzhou (CART-138/BCMA/19/more)

Recruiting
  • Multiple Myeloma
  • CART-138/BCMA/19/more
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Apr 30, 2019

Scleroderma, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Scleroderma
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Immune Nephritis, Autoimmune Diseases, Lupus Nephritis Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Immune Nephritis
  • +2 more
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Sjogren's Syndrome, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Sjogren's Syndrome
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Systemic Lupus Erythematosus, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Aug 31, 2021

Multiple Myeloma Trial in Hangzhou (T cell infusion agent targeting BCMA chimeric antigen receptor)

Completed
  • Multiple Myeloma
  • T cell infusion agent targeting BCMA chimeric antigen receptor
  • Hangzhou, Zhejiang, China
    No.3, Qingchun East Road
Nov 25, 2020

Relapsed/Refractory Multiple Myeloma(MM) Trial in Guangdong (CART therapy in Relapsed/Refractory multiple myeloma)

Terminated
  • Relapsed/Refractory Multiple Myeloma(MM)
  • CART therapy in Relapsed/Refractory multiple myeloma
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Sep 17, 2021

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Multiple Myeloma Trial in United States (Talquetamab)

Recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Sep 27, 2023

Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)

Recruiting
  • Multiple Myeloma
  • Human BCMA Targeted T Cells Injection
  • Shanghai, Shanghai, China
  • +1 more
Dec 7, 2022

Multiple Myeloma Trial in Beijing, Guangzhou, Shanghai (TQB2934 injection)

Not yet recruiting
  • Multiple Myeloma
  • TQB2934 injection
  • Beijing, Beijing, China
  • +2 more
Dec 8, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

RRMM Trial in Lishui, Wenzhou (CAR-T therapy in Relapsed/Refractory multiple myeloma)

Unknown status
  • RRMM
  • CAR-T therapy in Relapsed/Refractory multiple myeloma
  • Lishui, Zhejiang, China
  • +2 more
Nov 16, 2020

Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)

Enrolling by invitation
  • Multiple Myeloma
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
  • London, County (optional), United Kingdom
    University College London Hospital
Sep 15, 2022

Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)

Not yet recruiting
  • Multiple Myeloma
  • Allogeneic Stem Cell Transplantation
  • CARTemis-1
  • Santander, Cantabria, Spain
  • +4 more
Aug 1, 2023

Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • New Diagnosis Tumor
  • BCMA CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • VRD-based regimen
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023